U.S. President Donald Trump has announced plans to implement a significant tariff on pharmaceutical imports, aiming to incentivize drug companies to move their operations back to the United States. The tariff could heavily affect India’s pharmaceutical exports, which play a vital role in the U.S. healthcare system.

BulletsIn

• Trump confirmed plans to introduce a “major” tariff on pharmaceutical imports.
• The tariff aims to encourage pharmaceutical companies to shift production to the U.S.
• Previously, the Trump administration had exempted pharmaceuticals from its reciprocal tariff policy.
• India, a major supplier of medicines to the U.S., could face significant impact from these tariffs.
• India’s pharmaceutical exports were valued at USD 12.72 billion in 2024.
• Indian drugs account for 40% of U.S. prescriptions and contributed USD 219 billion in savings to the U.S. healthcare system in 2022.
• Indian generics are projected to save the U.S. an additional USD 1.3 trillion in the next five years.
• Experts warn that higher tariffs could increase production costs for Indian manufacturers and reduce their price competitiveness.
• The U.S. has already imposed a 26% reciprocal tariff on Indian goods due to New Delhi’s high import duties on American products.
• Trump also threatened to impose up to 100% taxes on TSMC if it does not build plants in the U.S.